September 2013 - FRMC

Volume
10
Issue 9
September 2013

FEATURES

The FDA approved Fulyzaq™ (crofelemer) in December 2012 to relieve noninfectious diarrhea in adults with HIV or AIDS who are taking anti-retroviral therapy. | Read More
Citation:

Tim Casey

Two phase 3 trials found that patients with moderate-to-severe chronic low back pain or osteoarthritis of the knee who experienced adverse events during the studies had problems associated with physical functioning, social functioning, mental health, and vitality. | Read More
Citation:

Tim Casey

In clinical practice, patients with moderate-to-severe chronic pain received doses of hydromorphone extended release that were nearly 50% lower than the doses given to patients who were prescribed oxymorphone extended release or oxycodone controlled release, according to prescription data. | Read More
Citation:

Tim Casey

Opioid medications have been proven effective in treating chronic pain; however, they are also associated with misuse, abuse, and diversion.  | Read More
Citation: